Karen M. Kuntz

Karen M. Kuntz

Auto-generated profile, based on publicly available information

Karen M. Kuntz

Department of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, Minnesota

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2011 in Medical Decision Making
Verified
Journal Article
Closed access
PDF file
KKKaren M. Kuntz
Karen M. Kuntz
ILIris Lansdorp-Vogelaar
Iris Lansdorp-Vogelaar
CRCarolyn M. Rutter
Carolyn M. Rutter
AKAmy B. Knudsen
Amy B. Knudsen
MBMarjolein van Ballegooijen
Marjolein van Ballegooijen
AZAnn G. Zauber
Ann G. Zauber
Background. As the complexity of microsimulation models increases, concerns about model transparency are heightened. Methods. The authors conducted model “experiments” to explore the impact of variations in “deep” model parameters using 3 colorectal cancer (CRC) models. All natural history models were calibrated to match observed data on adenoma prevalence and cancer incidence but varied in their underlying specification of the adenocarcinoma process. The authors projected CRC incidence among individuals with an underlying adenoma or preclinical cancer v. those without any underlying condition and examined the impact of removing adenomas. They calculated the percentage of simulated CRC cases arising from adenomas that developed within 10 or 20 years prior to cancer diagnosis and estimated dwell time—defined as the time from the development of an adenoma to symptom-detected cancer in the absence of screening among individuals with a CRC diagnosis. Results. The 20-year CRC incidence among 55-year-old individuals with an adenoma or preclinical cancer was 7 to 75 times greater than in the condition-free group. The removal of all adenomas among the subgroup with an underlying adenoma or cancer resulted in a reduction of 30% to 89% in cumulative incidence. Among CRCs diagnosed at age 65 years, the proportion arising from adenomas formed within 10 years ranged between 4% and 67%. The mean dwell time varied from 10.6 to 25.8 years. Conclusions. Models that all match observed data on adenoma prevalence and cancer incidence can produce quite different dwell times and very different answers with respect to the effectiveness of interventions. When conducting applied analyses to inform policy, using multiple models provides a sensitivity analysis on key (unobserved) “deep” model parameters and can provide guidance about specific areas in need of additional research and validation.

29 October 2007 in Population Health Metrics
Verified
Journal Article
Open access
PDF file
JGJeremy D Goldhaber-Fiebert
Jeremy D Goldhaber-Fiebert
NSNatasha K Stout
Natasha K Stout
JOJesse Ortendahl
Jesse Ortendahl
KKKaren M Kuntz
Karen M Kuntz
SGSue J Goldie
Sue J Goldie
JSJoshua A Salomon
Joshua A Salomon
To provide quantitative insight into current U.S. policy choices for cervical cancer prevention, we developed a model of human papillomavirus (HPV) and cervical cancer, explicitly incorporating uncertainty about the natural history of disease.

14 October 2019 in JNCI Cancer Spectrum
Verified
Journal Article
Open access
PDF file
SNSteffie K Naber
Steffie K Naber
SKSuman Kundu
Suman Kundu
KKKaren M Kuntz
Karen M Kuntz
WDWilliam David Dotson
William David Dotson
MWMarc Williams
Marc Williams
IVIris Lansdorp Vogelaar
Iris Lansdorp Vogelaar
Background: Although uniform colonoscopy screening reduces colorectal cancer (CRC) mortality, risk-based screening may be more efficient. We investigated whether CRC screening based on polygenic risk is a cost-effective alternative to current uniform screening, and if not, under what conditions it would be.Methods: The MISCAN-Colon model was used to simulate a hypothetical cohort of US 40-year-olds. Uniform screening was modeled as colonoscopy screening at ages 50, 60, and 70 years. For risk-stratified screening, individuals underwent polygenic testing with current and potential future discriminatory performance (area under the receiver-operating curve [AUC] of 0.60 and 0.65–0.80, respectively). Polygenic testing results were used to create risk groups, for which colonoscopy screening was optimized by varying the start age (40–60 years), end age (70–85 years), and interval (1–20 years).Results: With current discriminatory performance, optimal screening ranged from once-only colonoscopy at age 60 years for the lowest-risk group to six colonoscopies at ages 40–80 years for the highest-risk group. While maintaining the same health benefits, risk-stratified screening increased costs by $59 per person. Risk-stratified screening could become cost-effective if the AUC value would increase beyond 0.65, the price per polygenic test would drop to less than $141, or risk-stratified screening would lead to a 5% increase in screening participation.Conclusions: Currently, CRC screening based on polygenic risk is unlikely to be cost-effective compared with uniform screening. This is expected to change with a greater than 0.05 increase in AUC value, a greater than 30% reduction in polygenic testing costs, or a greater than 5% increase in adherence with screening.

27 June 2013 in Medical Decision Making
Verified
Journal Article
Open access
PDF file
HJHawre Jalal
Hawre Jalal
BDBryan Dowd
Bryan Dowd
FSFrançois Sainfort
François Sainfort
KKKaren M. Kuntz
Karen M. Kuntz
Background/Objective. Modelers lack a tool to systematically and clearly present complex model results, including those from sensitivity analyses. The objective was to propose linear regression metamodeling as a tool to increase transparency of decision analytic models and better communicate their results. Methods. We used a simplified cancer cure model to demonstrate our approach. The model computed the lifetime cost and benefit of 3 treatment options for cancer patients. We simulated 10,000 cohorts in a probabilistic sensitivity analysis (PSA) and regressed the model outcomes on the standardized input parameter values in a set of regression analyses. We used the regression coefficients to describe measures of sensitivity analyses, including threshold and parameter sensitivity analyses. We also compared the results of the PSA to deterministic full-factorial and one-factor-at-a-time designs. Results. The regression intercept represented the estimated base-case outcome, and the other coefficients described the relative parameter uncertainty in the model. We defined simple relationships that compute the average and incremental net benefit of each intervention. Metamodeling produced outputs similar to traditional deterministic 1-way or 2-way sensitivity analyses but was more reliable since it used all parameter values. Conclusions. Linear regression metamodeling is a simple, yet powerful, tool that can assist modelers in communicating model characteristics and sensitivity analyses.

6 June 2024 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
PLPedro Nascimento de Lima
Pedro Nascimento de Lima
RPRosita van Den Puttelaar
Rosita van Den Puttelaar
AKAmy B Knudsen
Amy B Knudsen
AHAnne I Hahn
Anne I Hahn
KKKaren M Kuntz
Karen M Kuntz
CRCarolyn M Rutter
Carolyn M Rutter
Background: Blood-based biomarker tests can potentially change the landscape of colorectal cancer (CRC) screening. We characterize the conditions under which blood test screening would be as effective and cost-effective as annual fecal immunochemical testing or decennial colonoscopy. Methods: We used the 3 Cancer Information and Surveillance Modeling Network–Colon models to compare scenarios of no screening, annual fecal immunochemical testing, decennial colonoscopy, and a blood test meeting Centers for Medicare & Medicaid (CMS) coverage criteria (74% CRC sensitivity and 90% specificity). We varied the sensitivity to detect CRC (74%-92%), advanced adenomas (10%-50%), screening interval (1-3 years), and test cost ($25-$500). Primary outcomes included quality-adjusted life-years (QALY) gained from screening and costs for a US average-risk cohort of individuals aged 45 years. Results: Annual fecal immunochemical testing yielded 125-163 QALY gained per 1000 at a cost of $3811-$5384 per person, whereas colonoscopy yielded 132-177 QALY gained at a cost of $5375-$7031 per person. A blood test with 92% CRC sensitivity and 50% advanced adenoma sensitivity yielded 117-162 QALY gained if used every 3 years and 133-173 QALY gained if used every year but would not be cost-effective if priced above $125 per test. If used every 3 years, a $500 blood test only meeting CMS coverage criteria yielded 83-116 QALY gained at a cost of $8559-$9413 per person. Conclusion: Blood tests that only meet CMS coverage requirements should not be recommended to patients who would otherwise undergo screening by colonoscopy or fecal immunochemical testing because of lower benefit. Blood tests need higher advanced adenoma sensitivity (above 40%) and lower costs (below $125) to be cost-effective.

1 September 2011 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
NKNeeraj Kumar
Neeraj Kumar
BBBradley F. Boeve
Bradley F. Boeve
BBBrendon P. Boot
Brendon P. Boot
COCarolyn F. Orr
Carolyn F. Orr
JDJoseph R. Duffy
Joseph R. Duffy
DDDennis W. Dickson
Dennis W. Dickson
Objective: To report the clinical, electroencephalographic, and neuroradiologic findings in a kindred with a novel insertion in the prion protein gene, PRNP.Design: Clinical description of a kindred.Setting: Mayo Clinic Alzheimer Disease Research Center (Rochester, Minnesota).Subjects: Two pathologically confirmed cases and their relatives.Main Outcome Measures: Clinical features, electroencephalographic patterns, magnetic resonance imaging abnormalities, genetic analyses, and neuropathologic features.Results: The proband was a woman with clinical and neuroimaging features of atypical frontotemporal dementia and ataxia. Generalized tonic-clonic seizures developed later in the disease course, and electroencephalography revealed spike and wave discharges but no periodic sharp-wave complexes. Her affected sister and father also exhibited frontotemporal dementia–like features, and both experienced generalized tonic-clonic seizures and gait ataxia late in the disease course. Genetic analyses in the proband identified a novel defect in PRNP, with 1 mutated allele carrying a 288–base pair insertion consisting of 12 octapeptide repeats. Neuropathologic examination of the proband and her sister revealed prion protein–positive plaques and widespread tau-positive tangles.Conclusions: This kindred has a unique combination of clinical and neuropathologic features associated with the largest base pair insertion identified to date in PRNP and underscores the need to consider familial prion disease in the differential diagnosis of a familial frontotemporal dementia–like syndrome.